DODriss Ait Ouakrim

Driss Ait Ouakrim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Driss Ait Ouakrim has a total of 260 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Interval colorectal cancer risk by haemoglobin concentration in Australia’s National Bowel Cancer Screening Program

    by Driss Ait Ouakrim, James Dowty, Jennifer McIntosh, Belinda Goodwin, Carlene Wilson, Katelyn Collins, Nick Ormiston-Smith, Pantea Konn, Glenn Austin, Eleonora Feletto, et al.

    Summary: Background: Interval colorectal cancers (CRCs) are an important measure of screening performance. We assessed interval CRC risk after negative faecal immunochemical testing (FIT), its association with faecal haemoglobin (f-Hb) concentration, and differences by age and sex in Australia s National Bowel Cancer Screening Program (NBCSP). Methods: We conducted a population-based retrospective cohort study linking Queensland screening and cancer registry records for NBCSP participants aged 50-74 years screened in 2018-2022. Eligible episodes had f-Hb below 20 ug/g in both samples. We excluded episodes with CRC diagnosed on or before follow-up start. Follow-up ended at CRC, the next screening episode, death, 24 months, or December 31, 2023. We estimated adjusted cause-specific hazard ratios (HRs), accounting for repeated episodes within participants, and cumulative incidence with death and subsequent screening as competing events. Findings: Among 1,083,149 negative screening episodes from 700,734 participants, 586 interval CRCs occurred over 2,056,405 person-years. The incidence rate was 28.5 per 100,000 person-years, and 24-month cumulative incidence was 57.6 per 100,000 episodes (95% CI 53.1-62.5). Risk increased with age and was higher in males (adjusted HR 1.28, 95% CI 1.08-1.50). The complete-case quantitative cohort included 326,931 episodes and 138 cancers. Compared with maximum f-Hb of 0-5 ug/g, concentrations >15-<20 ug/g were associated with an adjusted HR of 14.93 (9.02-24.70). Corresponding 24-month risks were 35.7 (28.5-44.7) and 504.5 (323.4-787.0) per 100,000 episodes. Higher negative-range f-Hb concentrations were more common in older participants and males. The quantitative cohort showed no clear sex difference after adjustment for f-Hb. Interpretation: CRC risk varies substantially among people with a negative screening result. Quantitative F-Hb levels may help identify who is at higher risk of interval CRC. Further research is needed to confirm these findings and assess the benefits, harms and costs of changing screening intervals. Research in context: Research in context: Evidence before this study: We searched PubMed October 2026, for Australian studies and international systematic reviews and meta-analyses, using combinations of “colorectal”, “bowel”, “interval cancer”, “interval cancers”, “interval colorectal”, “negative FIT”, “faecal haemoglobin”, “fecal hemoglobin”, “faecal immunochemical”, and “fecal immunochemical”, combined with “Australia”, “Australian”, “systematic review”, or “meta-analysis”. Additional searches examined international cohort studies published from January 1, 2020, to October 25, 2026. Australian national monitoring and a study in Western Australia showed that interval CRC was uncommon but more frequent among males and older participants. Both analyses were based on the 2018 screening cohort, before biennial screening had been fully implemented for all eligible people aged 50-74 years. Neither examined interval CRC risk across the negative f-Hb range. International reviews documented substantial variation in interval CRC incidence between screening programmes. More recent Danish and Dutch cohort studies showed that higher f-Hb concentrations below the positivity threshold were associated with greater interval CRC risk, including after successive negative screening rounds. A dose-response meta-analysis of 13 studies supported the prognostic value of negative-range f-Hb, but combined evidence on interval cancers, cancers detected at subsequent screening, and adenomas. These outcomes do not provide interchangeable estimates of risk before the next screen. The evidence therefore supported further investigation of quantitative f-Hb, but did not establish concentration-specific interval CRC risks for the NBCSP’s two-sample protocol and 20 µg/g positivity threshold. Added value of this study: This study extends Australian evidence through longitudinal linkage of Queensland screening and cancer registry records from 2018-2022, including repeated screening episodes from more than 700,000 participants. It estimates interval CRC risk overall and by age and sex, and examines how that risk varies within the negative f-Hb range. Follow-up ended at the next screening episode, allowing interval cancers to be distinguished from cancers detected at later screening. The quantitative analysis showed a substantial concentration gradient in both relative and absolute risk, despite all included results being classified as negative. By providing absolute risks within the Australian screening setting, the study offers evidence directly relevant to evaluating whether participants with different negative f-Hb concentrations could benefit from different screening intervals. Implications of all the available evidence: A negative FIT result provides reassurance, but does not indicate the same level of interval CRC risk for every participant. Together, the international evidence and our findings support evaluating screening strategies that use quantitative f-Hb rather than relying solely on a positive or negative result in the Australian program. They do not establish which screening intervals or thresholds should be adopted. Further evaluation should determine whether tailoring screening reduces interval cancers and advanced disease without disproportionate increases in colonoscopy use, harms, or inequalities in access and outcomes.

  • Modelling the impacts of illicit tobacco and e-cigarette market enforcement: Australian case study

    by Samantha Howe, Tim Wilson, Coral E Gartner, Tony Blakely, Driss Ait Ouakrim

    Background In Australia, daily smoking prevalence has fallen below 10% as of 2022–2023. However, prevalence of recent illicit tobacco use has increased, from 1.6% in 2019 to 3.8% in 2025. Recent policy changes have restricted e-cigarette sales to pharmacies, yet illicit supply remains widespread. We aimed to estimate how increasing enforcement against illicit tobacco and e-cigarettes might affect future smoking, vaping and mortality. Methods We used the SHINE-Tobacco simulation model that combines a Markov model of yearly smoking, vaping and dual use transitions, with a proportional multistate lifetable of tobacco-related diseases. We compare a ‘business-as-usual’ (BAU) scenario in which overall smoking declines (based on 2001–2022/2023 trends), but illicitly traded tobacco and e-cigarettes remain widespread, to four hypothetical enforcement scenarios starting in 2025 that vary by intensity (maximum 90% reduction) and whether increased pharmacy e-cigarette use occurs. Findings Under BAU, daily smoking prevalence declined from 9.1% in 2024 to 6.1% in 2044, while vaping increased from 4.8% to 9.9%. High illicit market enforcement reduced smoking to 4.5% and vaping to 1.3% by 2044. The largest reduction in smoking occurred under high illicit enforcement alongside ongoing e-cigarette use (via pharmacies) for smoking cessation, reducing smoking to 3.0% and averting 8370 deaths over 20 years (95% uncertainty interval 6970–10 100). While the model was moderately sensitive to changes in BAU assumptions, enforcement scenario rankings remained the same across sensitivity analyses. Conclusions Future smoking trajectories in Australia are likely to depend on both illicit product availability and the role of e-cigarettes in cessation. Future research is required to determine how hypothetical enforcement impacts could be achieved.

  • Open Access

    Modelling a tobacco-free generation policy in Australia: population health impacts under illicit market uncertainty

    by Samantha Howe, Tim Wilson, Coral Gartner, Tony Blakely, Driss Ait Ouakrim

    Objective: To estimate the potential health and equity impacts of a tobacco free generation (TFG) and T21 policy (increasing the legal age of sale to 21) in Australia, in the context of a complex market including widespread illicit tobacco and e-cigarette product availability. Design: A Markov macrosimulation model, parameterised with yearly net movements between legal smoking, illicit smoking, vaping, and dual use states, combined with a proportional multi-state lifetable. Setting: The Australian population, modelled as an open cohort for 40-years. Intervention: A ‘business-as-usual’ (BAU) scenario was compared to TFG and T21 policies, with both starting in 2026. Variations to policy impacts were tested under increasing background illicit market enforcement. Main outcome measures: The model estimates the health-adjusted life years (HALYs) and deaths over 40 years, under each scenario, with differences across age and socioeconomic status (SES) presented. Results: The TFG policy reduced daily smoking prevalence among 15-24-year-olds to 5.3% (95% uncertainty interval [UI] 4.8-6.0%) in 20 years’ time, compared to 7% under the T21 policy and 7.6% under BAU trends. Vaping was minimally impacted by either policy. The TFG policy resulted in 75,000 (95% UI 41,900-124,000) HALYs being gained over 40 years. The policy impact was larger when accompanied by increased illicit market enforcement, reducing daily smoking among 15-24-year-olds to 1·3% within 20 years. Both policies had greater prevalence and health impacts on more disadvantaged compared to advantaged SES groups. Conclusion: A TFG policy is expected to produce long-term benefits for the Australian population but would be most effective in combination with increased enforcement of illicit tobacco and e-cigarette markets. Novel strategies to increase quitting in addition to reducing uptake are needed to improve tobacco-related outcomes in the short to medium term. Plain language summary: The known: A ‘tobacco free generation (TFG)’ policy would theoretically minimise youth smoking uptake in Australia but may be undermined by rising illicit tobacco and e-cigarette use. The new: A TFG law in Australia may reduce daily smoking among 15-24-year-olds by 30% within 20 years, though resulting health impacts take longer to manifest. Larger impacts would also occur if smoking uptake via the illicit market was well controlled. The implications: A TFG policy could produce long-term benefits in Australia but should be implemented alongside policies to reduce illicit product supply and improve smoking cessation among adults who already smoke.

  • Open Access

    Modelling the Impacts of Illicit Market Enforcement on Smoking Prevalence: Australian Case Study

    by Samantha Howe, Tim Wilson, Coral Gartner, Tony Blakely, Driss Ait Ouakrim

    Background: In Australia, daily smoking prevalence has fallen to below 10% (as of 2022-23) but 50-60% of the tobacco market is now illicit. Recent policy changes have restricted e-cigarette sales to pharmacy access only, yet illicit supply remains widespread. We aimed to estimate how different levels of enforcement against illicit tobacco and e-cigarette markets might affect future smoking, vaping, and mortality in Australia.Methods: We used the SHINE Tobacco simulation model that combines a Markov model of yearly smoking, vaping, and dual use transitions, with a proportional multi-state lifetable of tobacco-related diseases. We compare a ‘business-as-usual’ (BAU) scenario in which overall smoking declines, but use of illicitly traded tobacco and e-cigarettes remain widespread. The BAU scenario was compared to four hypothetical enforcement scenarios starting in 2025. Scenarios varied by enforcement intensity (maximum 90% reduction) and whether enforcement reduced all use of illicitly traded e-cigarettes or only naïve vaping, allowing for continued legal access for smoking cessation. Outcomes were daily smoking and vaping prevalence to 2044, and deaths averted over 20 years.Findings: Under BAU, daily smoking prevalence among people aged 15 years and older declined from 9·4% in 2024 to 5·7% in 2044, while vaping increased from 4·8% to 9·8%. High enforcement targeting both illicit tobacco and e-cigarette markets reduced smoking to 4·5% and vaping to 2·4% by 2044. The largest reduction in smoking occurred under high enforcement targeting the illicit tobacco market and naïve vaping only, with continued access to e-cigarettes for cessation, reducing smoking to 3% and averting 4,840 deaths over 20 years (95% uncertainty interval 4,050–5,800). While the model was moderately sensitive to changes in BAU transition rates, the ranking of enforcement scenarios remained the same across sensitivity analyses. Interpretation: Future smoking trajectories in Australia are likely to depend on both availability of products in the illicit market and the role of e-cigarettes in cessation. Stronger enforcement could accelerate smoking declines, but policy choices require balancing reductions in smoking, total nicotine use, and short-term health gains.


  • Open Access

    Estimating the harms from smoking and second-hand smoke exposure in social housing: a modelling study

    by Samantha Howe, Tim Wilson, Kylie Morphett, Kate Mason, Germaine Lai, Vaughan W. Rees, Driss Ait Ouakrim


  • Open Access

    Estimating the harms from smoking and second-hand smoke exposure in social housing: a modelling study

    by Samantha Howe, Tim Wilson, Kylie Morphett, Kate Mason, Germaine Lai, Vaughan W. Rees, Driss Ait Ouakrim

    Background: People living in social housing in Australia have higher prevalence of daily smoking and greater exposure to second-hand smoke (SHS), particularly in multi-unit housing where smoke can drift between dwellings. The health impact of this exposure has not been quantified for this population. Methods: We developed a Monte-Carlo matrix model of household SHS exposure, including smoke drift between dwellings in multi-unit housing, and linked it to the SHINE Tobacco simulation platform. The model projected health outcomes for the population living in social housing in the state of Victoria, Australia, over 20 years, comparing scenarios that eradicated SHS exposure and/or smoking with a business-as-usual (BAU) scenario of constant smoking prevalence. Outcomes were health-adjusted life years (HALYs) gained, and premature deaths averted across 31 smoking-attributable and eight SHS-attributable diseases. Findings: Eradicating SHS exposure within the social housing population of Victoria in 2025 could result in 5,350 HALYs (95% uncertainty interval [UI] 4,670-6,120) gained, and 600 premature deaths (95% UI 500-700) averted over 20 years. In multi-unit housing, about half of the SHS-related health gain was attributable to eliminating smoke drift between units. Overall, SHS eradication accounted for approximately 27% of the total health gain achievable if tobacco smoking were fully eradicated in this setting. Interpretation: Reducing SHS exposure in social housing would deliver substantial health benefits, with a large share resulting from preventing smoke drift in multi-unit housing. Better data on population dynamics and smoke infiltration would strengthen estimates and support policy design. Funding: This research was funded by a seed funding grant awarded by the NHMRC Centre of Research Excellence on Achieving the Tobacco Endgame (NHMRC, GNT1198301)

  • Modelling the potential impacts of limiting vaping product sales to pharmacies

    by Driss Ait Ouakrim, Tim Wilson, Samantha Howe, Jennifer Summers, Richard Edwards, Coral E Gartner, Nick Wilson, Tony Blakely

    Background Vaping rates are increasing globally. Restricting vaping products’ access may result in net population health loss if youths who vape switch to smoking, or net gain if it promotes cessation among people who smoke. We used simulation modelling to assess how two vaping restriction policies—over-the-counter (OTC) pharmacy access or prescription-only access via general practitioners—might impact vaping and smoking rates in Aotearoa New Zealand (A/NZ). Methods We adapted an established Markov model of smoking and vaping, linked to a proportional multistate lifetable, to simulate the A/NZ population from 2023 to 2044. Three business-as-usual (BAU) scenarios (‘low’, ‘medium’ and ‘high’ vaping) were informed by youth vaping trends. Intervention impacts were derived from prior research and expert elicitation. Results Compared with the medium BAU scenario with 50% vaping among 18–24-year olds by 2044, restricting to OTC pharmacy access reduced vaping prevalence by 6% and increased health-adjusted life years (HALYs). Only under the ‘high’ BAU scenario (60% vaping) did interventions marginally increase smoking (2% for OTC). Both interventions averted premature deaths and produced HALY gains. Interpretation Our model suggests modest reductions in vaping prevalence and net health gains from the OTC pharmacy policy, with minor benefits from a prescription-only approach. These findings underscore the importance of balancing the potential smoking cessation benefits of vaping with the need to curb youth uptake. Future research is required to better understand how vaping restriction policies could impact vaping and smoking dynamics in A/NZ, in particular, considering how illicit supply may impact policy effectiveness.

  • Economic effects for citizens and the government of a country-level tobacco endgame strategy: a modelling study

    by Driss Ait Ouakrim, Tim Wilson, Samantha Howe, Philip Clarke, Coral E Gartner, Nick Wilson, Tony Blakely

    Background Aotearoa-New Zealand (A/NZ) was the first country to pass a comprehensive commercial tobacco endgame strategy into law. Key components include the denicotinisation of smoked tobacco products and a major reduction in tobacco retail outlets. Understanding the potential long-term economic impacts of such measures is important for government planning. Design A tobacco policy simulation model that evaluated the health impacts of the A/NZ Smokefree Action Plan was extended to evaluate the economic effects from both government and citizen perspectives. Estimates were presented in 2021 US$, discounted at 3% per annum. Results The modelled endgame policy package generates considerable growth in income for the A/NZ population with a total cumulative gain of US$31 billion by 2050. From a government perspective, increased superannuation payments and reduced tobacco excise tax revenue result in a negative net financial position and a cumulative shortfall of US$11.5 billion by 2050. In a sensitivity analysis considering future labour force changes, the government’s cumulative net position remained negative by 2050, but only by US$1.9 billion. Conclusions A policy such as the A/NZ Smokefree Action Plan is likely to produce substantial economic benefits for citizens, and modest impacts on government finances related to reduced tobacco tax and increases in aged pensions due to increased life expectancy. Such costs can be anticipated and planned for and might be largely offset by future increases in the size of the labour force and the proportion of people 65+ years old working in the formal economy.


  • Open Access

    Economic effects of a country-level tobacco endgame strategy: a modelling study

    by Driss Ait Ouakrim, Tim Wilson, Samantha Howe, Philip Clarke, Coral Gartner, Nick Wilson, Tony Blakely

    Background Aotearoa-New Zealand (A/NZ) is the first country to pass a comprehensive commercial tobacco endgame strategy into law. Key components include the denicotinisation of smoked tobacco products and a major reduction in tobacco retail outlets. Understanding the potential long-term economic impacts of these measures is important for government planning. Methods A tobacco policy simulation model that evaluated the health impacts of the A/NZ Smokefree Action Plan was extended to evaluate the economic effect of the new measures from both Government and citizen perspectives. Estimates were discounted at 3% per annum and presented in 2021 purchasing power parities US$. Findings The modelled endgame policy package generates considerable growth in income for the A/NZ population with a total cumulative gain by 2050 amounting to US$31 billion. From a government perspective, the policy results in foregone tobacco excise tax revenue with a negative net financial position estimated at US$11.5 billion by 2050. In a sensitivity analysis considering future changes to labour workforce, the government’s cumulative net position remained negative by 2050, but only by US$1.9 billion. Interpretation Our modelling suggests the Smokefree Aotearoa 2025 Action Plan is likely to produce substantial economic benefits for the A/NZ population, and modest impacts on government revenue and expenditure related to the reduction in tobacco tax and increases in aged pensions due to increased life expectancy. Such costs can be anticipated and planned for and might be largely offset by future increases in labour force and the proportion of 65+ year olds working in the formal economy. Funding This study was funded by a grant from the Australian National Health and Medical Research Council (GNT1198301) Evidence before this study Multiple countries have set targets to achieve a commercial tobacco endgame. Most simulation modelling studies have evaluated ‘traditional’ tobacco control interventions (e.g., tobacco excise tax increases, indoor smoking bans, smoking cessation health services). Very few have modelled the economic effects of endgame strategies. We searched PubMed with no language restrictions for articles published from 1 January 2000 to 8 February 2023 using the following search terms: (smoking[TW] OR tobacco[TW]) AND (endgame[TW] OR eliminat*[TW] OR “phasing out”[TW] OR “phase out”[TW] OR aboli*[TW] OR prohibit*[TW] OR ban[TW] OR “smoke free”[TW] OR “smoke-free”[TW]) AND (model*[TW] OR simulat*[TW]) AND (cost[TW] OR economic[TW]). We identified six economic evaluations of commercial tobacco endgame strategies, including different interventions and cost perspectives. Five studies modelled interventions in the Aotearoa/New Zealand (A/NZ) context and one in the UK. Four studies were conducted from a healthcare system perspective, estimating the costs to the health system associated with tobacco-related diseases. One of these studies additionally estimated ‘non-health social costs’, as the productivity loss resulting from smoking-associated morbidity and mortality. Another study estimated the cost to consumers resulting from a policy in which retail outlets selling tobacco were significantly reduced, considering both the actual cost of a pack of cigarettes and the cost of increased travel to retailers, and the last estimated excise tax revenue to the government resulting from increases to tobacco taxation (compared to no increases to current tobacco tax levels). Of the identified literature, none evaluated the effect of endgame strategies on citizen income nor the fiscal impacts to government revenue and expenditure. Added value of this study This study evaluates the economic impacts of a recently introduced commercial tobacco endgame legislation in A/NZ. We modelled the economic impacts by 2050 of a policy package that includes the four key measures in the new legislation (i.e., denicotinisation of smoked tobacco products, enhanced antismoking mass media campaigns, 90% reduction in the number of tobacco retail outlets, and a smoke-free generation law that bans sale of tobacco to anyone born after 2008). The analysis presents both a government and citizen perspective. The government fiscal impacts extend beyond health system expenditure to also include differences between business as usual (BAU) – i.e., no endgame strategy – and endgame scenarios in excise tax revenue, goods and services tax (GST) revenue, income tax revenue, and superannuation expenditure. A net government position is also calculated. The citizen perspective estimates the impact of the policy on population income and savings that may result from reduced tobacco consumption. Our model projects large economic gains for consumers from the tobacco endgame package resulting from a sharp reduction in smoking prevalence, morbidity and mortality. For the A/NZ Government, the policy is projected to result in reduced healthcare costs, and increased income tax and GST revenue. These gains are offset by increased superannuation payments resulting from a greater number of individuals living past the age at which superannuation is provided to all citizens (65 years in A/NZ and described in this article as “retirement age” for simplicity), as well as large reductions in excise tax revenue. Implication of all the available evidence Our findings support previous evidence indicating that ambitious tobacco control policies can produce large heath and economic benefits. Our model suggests that a commercial tobacco endgame strategy is likely to result in a large revenue transfer to the benefit of the A/NZ population. An endgame approach moves beyond the BAU model of incremental policy change to a deliberate strategy to permanently reduce tobacco smoking to minimal levels within a short timeframe. A logical result of such a strategy is a significant decrease in excise tax revenue for governments. Under the endgame scenario, the net position of the A/NZ Government is likely to be negative due mainly to the foregone excise tax revenue. In a sensitivity analysis of the endgame scenario that takes into account recent projections from Stats NZ of a future larger and older labour force in A/NZ, our model suggests that the net government position might become positive as early as 2036 – less than 15 years after the introduction of the endgame policy.


  • Open Access

    The Colorectal cancer RISk Prediction (CRISP) trial: a randomised controlled trial of a decision support tool for risk-stratified colorectal cancer screening

    by Jon D Emery, Mark A Jenkins, Sibel Saya, Patty Chondros, Jasmeen Oberoi, Shakira Milton, Kitty Novy, Emily Habgood, Napin Karnchanachari, Marie Pirotta, et al.

    Background: A risk-stratified approach to colorectal cancer (CRC) screening could result in a more acceptable balance of benefits and harms, and be more cost-effective.Aim: To determine the effect of a consultation in general practice using a computerised risk assessment and decision support tool (Colorectal cancer RISk Prediction, CRISP) on risk-appropriate CRC screening.Design and setting: Randomised controlled trial in 10 general practices in Melbourne, Australia, from May 2017 to May 2018.Method: Participants were recruited from a consecutive sample of patients aged 50–74 years attending their GP. Intervention consultations included CRC risk assessment using the CRISP tool and discussion of CRC screening recommendations. Control group consultations focused on lifestyle CRC risk factors. The primary outcome was risk-appropriate CRC screening at 12 months.Results: A total of 734 participants (65.1% of eligible patients) were randomised (369 intervention, 365 control); the primary outcome was determined for 722 (362 intervention, 360 control). There was a 6.5% absolute increase (95% confidence interval [CI] = −0.28 to 13.2) in risk-appropriate screening in the intervention compared with the control group (71.5% versus 65.0%; odds ratio [OR] 1.36, 95% CI = 0.99 to 1.86,P= 0.057). In those due CRC screening during follow-up, there was a 20.3% (95% CI = 10.3 to 30.4) increase (intervention 59.8% versus control 38.9%; OR 2.31, 95% CI = 1.51 to 3.53,P<0.001) principally by increasing faecal occult blood testing in those at average risk.Conclusion: A risk assessment and decision support tool increases risk-appropriate CRC screening in those due screening. The CRISP intervention could commence in people in their fifth decade to ensure people start CRC screening at the optimal age with the most cost-effective test.